Frontier Wealth Management LLC reduced its position in shares of Astrazeneca PLC (NYSE:AZN) by 4.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,972 shares of the company’s stock after selling 1,950 shares during the period. Frontier Wealth Management LLC’s holdings in Astrazeneca PLC were worth $1,065,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Acrospire Investment Management LLC raised its position in Astrazeneca PLC by 1,078.4% in the third quarter. Acrospire Investment Management LLC now owns 3,606 shares of the company’s stock worth $118,000 after buying an additional 3,300 shares during the period. Asset Planning Services Ltd. raised its position in Astrazeneca PLC by 628.6% in the fourth quarter. Asset Planning Services Ltd. now owns 5,100 shares of the company’s stock worth $139,000 after buying an additional 4,400 shares during the period. Yorktown Management & Research Co Inc acquired a new position in Astrazeneca PLC during the third quarter worth $210,000. Princeton Alpha Management LP acquired a new position in Astrazeneca PLC during the third quarter worth $210,000. Finally, Parkside Financial Bank & Trust raised its position in Astrazeneca PLC by 7.7% in the third quarter. Parkside Financial Bank & Trust now owns 6,390 shares of the company’s stock worth $210,000 after buying an additional 455 shares during the period. 12.90% of the stock is owned by hedge funds and other institutional investors.
Astrazeneca PLC (NYSE:AZN) traded up 0.37% during trading on Monday, reaching $29.64. The company’s stock had a trading volume of 5,482,650 shares. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.04. The stock has a 50 day moving average price of $27.95 and a 200 day moving average price of $30.00. The stock has a market capitalization of $74.99 billion, a PE ratio of 21.48 and a beta of 0.77.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, February 2nd. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.62. Astrazeneca PLC had a return on equity of 34.30% and a net margin of 15.21%. The company had revenue of $5.59 billion for the quarter, compared to the consensus estimate of $5.43 billion. During the same period last year, the business posted $0.94 EPS. The company’s revenue was down 12.7% on a year-over-year basis. Analysts anticipate that Astrazeneca PLC will post $1.82 earnings per share for the current fiscal year.
The business also recently announced a semiannual dividend, which will be paid on Monday, March 20th. Shareholders of record on Friday, February 17th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Wednesday, February 15th. This represents a dividend yield of 6.81%. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 49.64%.
“Frontier Wealth Management LLC Sells 1,950 Shares of Astrazeneca PLC (AZN)” was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this story on another website, it was stolen and republished in violation of US & international trademark and copyright law. The correct version of this story can be accessed at http://sleekmoney.com/frontier-wealth-management-llc-sells-1950-shares-of-astrazeneca-plc-azn/1659198.html.
AZN has been the subject of a number of recent research reports. Liberum Capital raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Friday, November 25th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, October 28th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, October 28th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, November 7th. Finally, Bank of America Corporation reaffirmed a “buy” rating and set a $41.37 price objective on shares of Astrazeneca PLC in a research note on Thursday, November 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company. Astrazeneca PLC has a consensus rating of “Buy” and an average price target of $34.44.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/frontier-wealth-management-llc-sells-1950-shares-of-astrazeneca-plc-azn/1659198.html
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.